Boris Kerzner

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.

Moti L. Kashyap, Mark E. McGovern, Kathleen Berra et al. · The American Journal of Cardiology · 2002 · 234 citations

Drug Safety, Cardiovascular Disease, Medicine +6

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

Boris Kerzner, John Corbelli, Stephan C. Sharp et al. · The American Journal of Cardiology · 2003 · 217 citations

Thrombosis, Primary Hypercholesterolemia, Lipid Disorder +9

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

Harold Bays, Sherwyn Schwartz, Thomas Littlejohn et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 146 citations · Full text

Adverse drug reactions—a matter of opinion

Fred E. Karch, Carol L. Smith, Boris Kerzner et al. · Clinical Pharmacology & Therapeutics · 1976 · 140 citations